Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DVAX Dynavax Technologies	$9.85 +4.7%	$12.16	$9.28 ▼ $14.63	$1.18B	1.26	2.22 million shs	4.46 million shs
LGND Ligand Pharmaceuticals	$106.38 +1.8%	$106.41	$77.43 ▼ $129.90	$2.05B	0.87	116,915 shs	141,251 shs
SMMT Summit Therapeutics	$25.26 +5.4%	$22.06	$2.10 ▼ $36.91	$18.76B	-0.94	3.85 million shs	3.03 million shs
VKTX Viking Therapeutics	$28.30 +2.7%	$26.19	$18.92 ▼ $81.73	$3.09B	0.75	4.09 million shs	3.77 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DVAX Dynavax Technologies	+4.68%	-12.52%	-12.44%	-22.44%	-8.20%
LGND Ligand Pharmaceuticals	+1.82%	+0.03%	+2.02%	-5.67%	+21.88%
SMMT Summit Therapeutics	+5.43%	-9.85%	+8.69%	+32.39%	+443.23%
VKTX Viking Therapeutics	+2.50%	-4.04%	+27.36%	-5.54%	-61.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DVAX Dynavax Technologies	4.3254 of 5 stars	3.3	2.0	4.7	2.5	1.7	1.9
LGND Ligand Pharmaceuticals	4.4284 of 5 stars	3.5	0.0	4.4	3.9	2.5	1.9
SMMT Summit Therapeutics	2.909 of 5 stars	4.5	1.0	0.0	4.0	1.7	0.0
VKTX Viking Therapeutics	4.6707 of 5 stars	4.5	2.0	4.7	3.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.00	143.65% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$146.14	37.38% Upside
SMMT Summit Therapeutics	3.09	Buy	$37.40	48.06% Upside
VKTX Viking Therapeutics	3.00	Buy	$87.15	207.96% Upside

Current Analyst Ratings Breakdown

Latest VKTX, DVAX, SMMT, and LGND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00
5/8/2025	SMMT Summit Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/7/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $31.00
5/2/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $41.00
4/29/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
4/28/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00 ➝ $40.00
4/28/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$104.00
4/28/2025	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$95.00 ➝ $75.00
4/25/2025	SMMT Summit Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$31.00 ➝ $44.00
4/24/2025	VKTX Viking Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$105.00 ➝ $102.00

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DVAX Dynavax Technologies	$294.62M	4.01	N/A	N/A	$4.81 per share	2.05
LGND Ligand Pharmaceuticals	$181.49M	11.30	$4.36 per share	24.39	$40.39 per share	2.63
SMMT Summit Therapeutics	$700K	26,799.63	N/A	N/A	$0.11 per share	229.64
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$3.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DVAX Dynavax Technologies	-$6.39M	-$0.52	54.72	20.10	N/A	9.85%	4.22%	2.67%	N/A
LGND Ligand Pharmaceuticals	$52.15M	-$7.12	42.38	28.67	N/A	29.68%	4.95%	4.39%	N/A
SMMT Summit Therapeutics	-$614.93M	-$0.34	N/A	N/A	N/A	N/A	-85.42%	-52.66%	N/A
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-11.93%	-11.57%	7/23/2025 (Estimated)

Latest VKTX, DVAX, SMMT, and LGND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/6/2025	Q1 2025	DVAX Dynavax Technologies	$0.03	-$0.11	-$0.14	-$0.77	$70.01 million	$68.16 million
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A
2/24/2025	Q4 2024	SMMT Summit Therapeutics	-$0.08	-$0.08	N/A	-$0.08	N/A	$0.20 million
2/20/2025	Q4 2024	DVAX Dynavax Technologies	$0.05	$0.05	N/A	$0.05	$72.70 million	$72.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DVAX Dynavax Technologies	0.33	13.23	12.34
LGND Ligand Pharmaceuticals	N/A	12.49	11.81
SMMT Summit Therapeutics	N/A	8.31	8.31
VKTX Viking Therapeutics	N/A	36.47	36.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DVAX Dynavax Technologies	96.96%
LGND Ligand Pharmaceuticals	91.28%
SMMT Summit Therapeutics	4.61%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
DVAX Dynavax Technologies	2.98%
LGND Ligand Pharmaceuticals	5.90%
SMMT Summit Therapeutics	88.30%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DVAX Dynavax Technologies	350	120.08 million	127.54 million	Optionable
LGND Ligand Pharmaceuticals	80	19.28 million	17.78 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	86.28 million	Optionable
VKTX Viking Therapeutics	20	112.31 million	106.20 million	Optionable

VKTX, DVAX, SMMT, and LGND Headlines

Recent News About These Companies

Ameriprise Financial Inc. Has $59.54 Million Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 13 at 4:48 AM | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Buy" by Analysts

May 13 at 2:25 AM | marketbeat.com

Granahan Investment Management LLC Has $12.30 Million Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 12 at 6:35 AM | marketbeat.com

FORA Capital LLC Makes New $1.12 Million Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 12 at 5:43 AM | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Fred Alger Management LLC

May 12 at 5:43 AM | marketbeat.com

Hsbc Holdings PLC Sells 9,437 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 12 at 3:44 AM | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Consensus Rating of "Buy" from Brokerages

May 12 at 2:29 AM | americanbankingnews.com

3 Monster Stocks in the Making

May 11 at 11:15 AM | fool.com

Frontier Capital Management Co. LLC Purchases 16,321 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 11 at 7:17 AM | marketbeat.com

Comerica Bank Reduces Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 11 at 4:42 AM | marketbeat.com

DAFNA Capital Management LLC Lowers Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 10 at 7:30 AM | marketbeat.com

Boone Capital Management LLC Boosts Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 8, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Position Lifted by Braidwell LP

May 8, 2025 | marketbeat.com

Aptus Capital Advisors LLC Purchases 10,564 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 8, 2025 | marketbeat.com

Cantor Fitzgerald L. P. Takes $380,000 Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 7, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Bamco Inc. NY

May 7, 2025 | marketbeat.com

AQR Capital Management LLC Boosts Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 6, 2025 | marketbeat.com

Why Viking Therapeutics Stock Surged Nearly 20% Higher in April

May 6, 2025 | fool.com

Apis Capital Advisors LLC Has $3.86 Million Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 5, 2025 | marketbeat.com

5AM Venture Management LLC Has $7.63 Million Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 4, 2025 | marketbeat.com

683 Capital Management LLC Lowers Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
By Chris Markoch | April 16, 2025
View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
Viking Therapeutics Stock Pops But Struggles to Hold Gains
By Chris Markoch | April 16, 2025
View Viking Therapeutics Stock Pops But Struggles to Hold Gains
Viking Therapeutics Stock May Struggle After As-Expected Report
By Chris Markoch | April 25, 2025
View Viking Therapeutics Stock May Struggle After As-Expected Report

VKTX, DVAX, SMMT, and LGND Company Descriptions

Dynavax Technologies NASDAQ:DVAX

$9.85 +0.44 (+4.68%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$9.78 -0.07 (-0.70%)

As of 04:05 AM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Ligand Pharmaceuticals NASDAQ:LGND

$106.38 +1.90 (+1.82%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$106.60 +0.23 (+0.21%)

As of 04:21 AM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Summit Therapeutics NASDAQ:SMMT

$25.26 +1.30 (+5.43%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$24.82 -0.44 (-1.74%)

As of 04:07 AM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Viking Therapeutics NASDAQ:VKTX

$28.30 +0.75 (+2.72%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$28.40 +0.10 (+0.35%)

As of 04:27 AM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time